Archived
Joint Association & Institutional Letter to President Trump on Fetal Tissue Research Restrictions and COVID-19
The letter, dated March 25, 2020, is a joint appeal from numerous leading scientific, medical, and patient advocacy organizations to President Donald J. Trump. The signatories urge a reconsideration and immediate lifting of federal restrictions on research involving human fetal tissue, emphasizing the critical role such research plays in developing treatments and vaccines during the COVID-19 pande
Frequently Asked Questions Regarding COVID-19’s Impact on Federal Awards (Version 2.0)
The document provides a comprehensive update on federal funding agency guidance and flexibilities in response to the disruptions caused by the COVID-19 pandemic. The Office of Management and Budget (OMB) has directed federal agencies to provide short-term administrative and financial relief, although implementation of these flexibilities varies by agency. Some agencies, such as the NIH, have permi
Track Changes Version of Proposed Revisions to Uniform Guidance – January 22, 2020
The document provides an extensive, authoritative framework for the administration, management, and oversight of federal awards to non-federal entities, principally through revisions to Title 2 of the Code of Federal Regulations (2 CFR). Its primary aim is to advance government priorities, such as the President’s Management Agenda and the Results-Oriented Accountability for Grants initiative, by r
COGR February 2019 Meeting Report
The February 28-March 1, 2019 meeting of the Council on Governmental Relations (COGR) addressed a broad spectrum of issues affecting research institutions, with a strong emphasis on science and security. The report outlines growing federal concerns related to foreign influence on U.S. research, particularly regarding the potential for illicit transfer or misuse of sensitive data and intellectual p
COGR Research Regulatory Reform Matrix
The document provides a detailed overview of federal efforts to address regulatory burden and reform policies related to federally funded research, based on statutory requirements from acts such as the 21st Century Cures Act and the American Innovation and Competitiveness Act (AICA). Key reform areas include the establishment of a Research Policy Board, interagency working groups, harmonization of
Research Project Support Costs Work Group
The provided document appears to be largely composed of a mix of symbols and partially coherent text, which makes full interpretation challenging. However, it is possible to discern that the content is structured to address topics related to procedures, evaluations, and possibly instructions within an organizational or academic context. The document references steps or methods for carrying out act
